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Editor,
P egaptanib sodium (Macugen; Eye-tech Pharmaceuticals/Pﬁzer Inc,
New York, NY, USA) is an antivascu-
lar endothelial growth factor (anti-
VEGF) aptamer that speciﬁcally
blocks the 165 isoform. It is currently
FDA approved for treating neovascu-
lar age-related macular degeneration
(Gragoudas et al. 2004). Macugen has
also been shown to decrease central
retinal thickness, improve visual acuity
and reduce the need for additional
photocoagulation in patients with dia-
betic macula oedema (DME) (Cunn-
ingham et al. 2005) and branch retinal
vein occlusion (BRVO) (Wroblewski
et al. 2010). Although the eﬀects of
anti-VEGF drugs on retinal structure
appear promising, their eﬀects on
the ocular vasculature are not well
studied. The mechanism of anti-VEGF
treatments suggests a potential for
interaction with the ocular circulation.
To the best of our knowledge, we
report for the ﬁrst time the eﬀects of
Macugen on retrobulbar and retinal
haemodynamics.
This was a prospective, open-label
case series involving patients with mac-
ular oedema caused by DM or branch
RVO. Patients were diagnosed at the
ophthalmology clinics of the Indiana
University School of Medicine. All
study procedures conformed to the
tenets of the Declaration of Helsinki
and were approved by the University
Institutional Review Board. Subjects
were informed that Macugen is FDA
approved for AMD but is being utilized
as an oﬀ-label indication in DME and
BRVO. Primary outcome measures
were the changes in both retrobulbar
and retinal circulation (measured by
colour Doppler imaging and Heidel-
berg Retinal Flowmetry, respectively),
as well as the change in macular thick-
ness as measured by optical coherence
tomography (OCT). Eight patients
were enrolled in the study (mean age
58.5 (16.2) years, ﬁve female). Six
were diagnosed with macular oedema
due to diabetic maculopathy and two
due to BRVO. After baseline measure-
ments were taken, the injections were
performed every 6 weeks for three
injection cycles. Measurements were
taken at each visit prior to injection.
Patients were given an additional injec-
tion at 18 weeks if there was residual
macular oedema (OCT thickness
>250 lm) after the ﬁrst three injections.
Macugen caused a statistically sig-
niﬁcant reduction in blood ﬂow veloc-
ity of the central retinal artery (CRA)
after the 3rd injection as compared to
preinjection (Table 1). The drug did
not signiﬁcantly aﬀect velocity or resis-
tance index in the ophthalmic artery or
short posterior ciliary arteries. Baseline
values of superior and inferior mean
retinal capillary blow ﬂow were 450.9
and 451.7 and after the third Macugen
injection were 525.5 and 406.9, respec-
tively; this was not a statistically sig-
niﬁcant alteration (p = 0.094 and 0.37,
respectively). Visual acuity was not
statistically signiﬁcantly altered after
each study visit. Macular thickness
showed a trend of reduction in every
OCT parameter at nearly every visit;
however, only one visit and parameter
(macular outer inferior region thick-
ness after ﬁrst injection) reached
statistical signiﬁcance.
Our data suggest that Macugen
injections may reduce CRA blood ﬂow
velocities with repeated treatments as
part of a cumulative eﬀect. A single
injection of another anti-VEGF treat-
ment, bevacizumab, has been shown
to decrease blood ﬂow velocity in all
retrobulbar arteries (Bonnin et al. 2010).
A larger study with accompanying
Table 1. Colour doppler imaging of the retrobulbar blood vessels.
Baseline
mean
(SD)
Post inj 1
mean
(SD)
Post inj
2 mean
(SD)
Post inj
3 mean
(SD)
T-test post
inj 1 versus
base
T-test post inj
2 versus
base
T-test post inj
3 versus
base
T-test post
versus
pre-inj 2
T-test post
versus
pre-inj 3
OA PSV 19.7 (8.9) 21 (4.3) 24.4 (7.9) 24.7 (9.6) 0.99 0.18 0.33 0.28 0.71
OA EDV 4.5 (1.6) 5.8 (1.6) 5.9 (1.7) 5.6 (3.0) 0.21 0.08 0.33 0.92 0.86
OA Rl 0.75 (0.05) 0.68 (0.09) 0.76 (0.05) 0.78 (0.06) 0.19 0.7 0.93 0.24 0.268
CRA PSV 6.6 (2.0) 7.7 (2.6) 8.1 (2.4) 6.9 (1.9) 0.22 0.18 0.6 0.44 0.02*
CRA EDV 2.4 (0.8) 2.6 (0.4) 2.7 (0.5) 2.0 (0.6) 0.49 0.13 1 0.83 0.01*
CRA Rl 0.63 (0.07) 0.64 (0.1) 0.66 (0.05) 0.7 (0.06) 0.73 0.79 0.37 0.36 0.11
TPCA PSV 8.3 (1.7) 7.0 (1.4) 8.3 (1.1) 7.9 (1.6) 0.095 0.15 0.25 0.03 1
TPCA EDV 3.2 (0.8) 3.2 (1.6) 3.1 (0.7) 2.7 (0.5) 0.9 0.37 0.72 0.84 0.37
TPCA Rl 0.6 (0.05) 0.63 (0.07) 0.63 (0.07) 0.66 (0.05) 0.6 0.5 0.93 0.85 0.38
NPCA PSV 8.1 (1.8) 6.9 (0.5) 7.5 (0.7) 7.2 (1.5) 0.35 0.61 0.82 0.24 0.64
NPCA EDV 3.2 (0.6) 2.4 (0.4) 2.5 (0.3) 2.3 (0.4) 0.1 0.63 0.26 0.82 0.48
NPCA Rl 0.6 (0.05) 0.65 (0.06) 0.67 (0.04) 0.67 (0.04) 0.18 0.32 0.23 0.76 0.64
OA, ophthalmic artery; CRA, central retinal artery; TPCA, temporal short posterior ciliary arteries; NPCA, nasal short posterior ciliary artery; PSV,
peak systolic velocities (cm/s); EDV, end diastolic velocities (cm/s); RI, vascular resistance index.
* statistically signiﬁcant.
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controls may help elucidate the pres-
ence or absence of any cumulative
eﬀects of Macugen in these other ret-
robulbar blood vessels.
In our analysis, retinal capillary
blood ﬂow was not altered by Macu-
gen. Another pilot study found a sig-
niﬁcant decrease in the retinal
arteriolar diameter after each intravi-
treal injection of ranibizumab (Papad-
opoulou et al. 2009). Taken together
with our results, this suggests that anti-
VEGF injections may reduce blood
supply to the retina; however, data
are not consistent, and the potential
eﬀects in patients with macular oedema
both secondary to DR and BRVO
require further veriﬁcation.
Our study is limited by small sample
size and lack of a control group.
Therefore, a period eﬀect cannot be
ruled out from the current ﬁndings.
Additionally, vessel diameter was not
examined in the study. In conclusion,
Macugen caused a signiﬁcant reduction
in CRA blood ﬂow velocity after
repeated treatments, although the
other retrobulbar and retinal vessels
did not show signiﬁcant haemody-
namic changes.
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